SI1576182T2 - Izboljšava kvalitete izdelka v procesih pridelave beljakovin v celični kulturi sesalcev - Google Patents

Izboljšava kvalitete izdelka v procesih pridelave beljakovin v celični kulturi sesalcev

Info

Publication number
SI1576182T2
SI1576182T2 SI200331927T SI200331927T SI1576182T2 SI 1576182 T2 SI1576182 T2 SI 1576182T2 SI 200331927 T SI200331927 T SI 200331927T SI 200331927 T SI200331927 T SI 200331927T SI 1576182 T2 SI1576182 T2 SI 1576182T2
Authority
SI
Slovenia
Prior art keywords
galactose
culture
sialylation
cell culture
methods
Prior art date
Application number
SI200331927T
Other languages
English (en)
Other versions
SI1576182T1 (sl
Inventor
Bernhard M. Schilling
Scott Gangloff
Dharti Kothari
Kirk Leister
Linda Matlock
Stephen G. Zegarelli
Christoph E. Joosten
Jonathan O. Basch
Sivakesava Sakhamuri
Steven S. Lee
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32682324&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI1576182(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of SI1576182T1 publication Critical patent/SI1576182T1/sl
Publication of SI1576182T2 publication Critical patent/SI1576182T2/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/34—Sugars
SI200331927T 2002-12-23 2003-12-18 Izboljšava kvalitete izdelka v procesih pridelave beljakovin v celični kulturi sesalcev SI1576182T2 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43605002P 2002-12-23 2002-12-23
EP03808535.3A EP1576182B2 (en) 2002-12-23 2003-12-18 Product quality enhancement in mammalian cell culture processes for protein production
PCT/US2003/040939 WO2004058944A2 (en) 2002-12-23 2003-12-18 Product quality enhancement in mammalian cell culture processes for protein production

Publications (2)

Publication Number Publication Date
SI1576182T1 SI1576182T1 (sl) 2011-01-31
SI1576182T2 true SI1576182T2 (sl) 2020-07-31

Family

ID=32682324

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200331927T SI1576182T2 (sl) 2002-12-23 2003-12-18 Izboljšava kvalitete izdelka v procesih pridelave beljakovin v celični kulturi sesalcev

Country Status (22)

Country Link
US (2) US7332303B2 (sl)
EP (1) EP1576182B2 (sl)
JP (1) JP4496086B2 (sl)
KR (1) KR101088223B1 (sl)
CN (1) CN100402660C (sl)
AT (1) ATE488600T1 (sl)
AU (1) AU2003303394B2 (sl)
BR (1) BR0316882A (sl)
CA (1) CA2508925C (sl)
CO (1) CO5590971A2 (sl)
CY (1) CY1111358T1 (sl)
DE (1) DE60335024D1 (sl)
DK (1) DK1576182T4 (sl)
ES (1) ES2354610T5 (sl)
HK (1) HK1075474A1 (sl)
IL (1) IL168873A (sl)
MX (1) MXPA05006522A (sl)
PL (1) PL377603A1 (sl)
PT (1) PT1576182E (sl)
SI (1) SI1576182T2 (sl)
TW (1) TWI328614B (sl)
WO (1) WO2004058944A2 (sl)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887471B1 (en) 1991-06-27 2005-05-03 Bristol-Myers Squibb Company Method to inhibit T cell interactions with soluble B7
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US20030219863A1 (en) * 1997-01-31 2003-11-27 Bristol-Myers Squibb Company Soluble CTLA4 mutant molecules and uses thereof
ZA98533B (en) * 1997-01-31 1999-07-22 Bristol Myers Squibb Co Soluble CTLA4 mutant molecules and uses thereof.
US7297680B2 (en) 1999-04-15 2007-11-20 Crucell Holland B.V. Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
US7754208B2 (en) * 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) * 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
JP4837880B2 (ja) 2001-05-23 2011-12-14 ブリストル−マイヤーズ スクイブ カンパニー 可溶性ｃｔｌａ４突然変異体分子を使って同種異系島移植片を保護する方法
MXPA05006523A (es) 2002-12-23 2005-08-26 Squibb Bristol Myers Co Procesos de cultivo de celulas de mamiferos para la produccion de proteinas.
WO2004058944A2 (en) * 2002-12-23 2004-07-15 Bristol-Myers Squibb Company Product quality enhancement in mammalian cell culture processes for protein production
NZ542585A (en) * 2003-05-09 2007-11-30 Crucell Holland Bv Cultures of PER.C6-immortalized cells and processes for culturing the same to increase product yields therefrom
US7754209B2 (en) * 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
MXPA06001225A (es) 2003-08-04 2006-04-11 Bristol Myers Squibb Co Metodos de tratamiento de enfermedad cardiovascular usando una molecula soluble de ctla4.
US7815765B2 (en) * 2004-04-01 2010-10-19 Swei Mu Wang Method for forming laminated synthetic leather
BRPI0608144A2 (pt) 2005-04-06 2009-11-17 Bristol Myers Squibb Co uso de uma molécula mutante de ctla4
ES2539250T3 (es) 2005-07-25 2015-06-29 Emergent Product Development Seattle, Llc Reducción de células B mediante el uso de moléculas de unión específica a CD37 y de unión específica a CD20
WO2008057634A2 (en) * 2006-10-26 2008-05-15 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
US8470318B2 (en) 2005-11-07 2013-06-25 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
TW201008595A (en) 2005-12-20 2010-03-01 Bristol Myers Squibb Co Stable protein formulations
US9309316B2 (en) 2005-12-20 2016-04-12 Bristol-Myers Squibb Company Stable subcutaneous protein formulations and uses thereof
AR058568A1 (es) 2005-12-20 2008-02-13 Bristol Myers Squibb Co Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
ES2439641T3 (es) 2005-12-20 2014-01-24 Bristol-Myers Squibb Company Composiciones y procedimientos de producción de una composición
MX2008012843A (es) * 2006-04-05 2009-01-19 Univ Rockefeller Polipeptidos con propiedades antiinflamatorias aumentadas y citotoxicas reducidas y metodos relacionados.
SG172698A1 (en) * 2006-06-12 2011-07-28 Trubion Pharmaceuticals Inc Single-chain multivalent binding proteins with effector function
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
SG174804A1 (sl) 2006-09-13 2011-10-28 Abbott Lab
DK2115126T3 (en) 2007-03-02 2015-05-04 Wyeth Llc Use of copper and glutamate in cell culture for the preparation of polypeptides
PT2222697E (pt) * 2007-11-01 2013-02-15 Perseid Therapeutics Llc Polipeptídeos imunossupressores e ácidos nucleicos
NZ603059A (en) * 2008-04-11 2014-07-25 Emergent Product Dev Seattle Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
AU2009240637A1 (en) 2008-04-22 2009-10-29 The Rockefeller University Methods of identifying anti-inflammatory compounds
US7915222B2 (en) 2008-05-05 2011-03-29 Bristol-Myers Squibb Company Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis
KR101722423B1 (ko) 2008-10-20 2017-04-18 애브비 인코포레이티드 항체 정제 동안의 바이러스 불활성화
BRPI0920027A2 (pt) * 2008-10-20 2015-10-06 Abbott Lab isolamento e purificação de anticorpos usando cromatografia de afinidade a proteína a
US9540426B2 (en) 2009-10-06 2017-01-10 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
US20110262965A1 (en) * 2010-04-23 2011-10-27 Life Technologies Corporation Cell culture medium comprising small peptides
WO2011134919A2 (en) 2010-04-26 2011-11-03 Novartis Ag Improved cell cultivation process
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
EP2729561A4 (en) 2011-07-08 2015-06-24 Momenta Pharmaceuticals Inc CELL CULTURE METHOD
WO2013114165A1 (en) * 2012-01-30 2013-08-08 Dr Reddy's Laboratories Limited Process of obtaining glycoprotein composition with increased afucosylation content
EP2809773B1 (en) 2012-01-30 2020-09-02 Dr. Reddy's Laboratories Limited Process of modulating man5 and/or afucosylation content of glycoprotein composition
EP2809772A4 (en) * 2012-01-30 2015-06-03 Reddys Lab Ltd Dr PROCESS FOR PREPARING GLYCOPROTEIN COMPOSITION
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
EP2844737B1 (en) 2012-05-02 2018-03-21 Life Technologies Corporation High yield transient expression in mammalian cells using unique pairing of high density growth and transfection medium and expression enhancers
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
HUE047077T2 (hu) 2012-06-29 2020-04-28 Bristol Myers Squibb Co Eljárások glikoprotein aggregáció csökkentésére
US9664671B2 (en) 2012-07-24 2017-05-30 Nissan Chemical Industries, Ltd. Culture medium composition and method of culturing cell or tissue using thereof
JP6218285B2 (ja) * 2012-08-23 2017-10-25 日産化学工業株式会社 タンパク質産生促進剤
US10017805B2 (en) 2012-08-23 2018-07-10 Nissan Chemical Industries, Ltd. Enhancing ingredients for protein production from various cells
WO2014035475A1 (en) 2012-09-02 2014-03-06 Abbvie Inc. Methods to control protein heterogeneity
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
US20140106405A1 (en) * 2012-10-15 2014-04-17 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
EP2906683B1 (en) 2012-10-15 2017-05-31 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
EP2830651A4 (en) 2013-03-12 2015-09-02 Abbvie Inc HUMAN ANTIBODIES THAT BIND TNF-ALPHA AND PREPARATION METHODS
WO2014151878A2 (en) * 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US9217168B2 (en) 2013-03-14 2015-12-22 Momenta Pharmaceuticals, Inc. Methods of cell culture
TWI720289B (zh) * 2013-03-14 2021-03-01 美商安美基公司 用於增加重組蛋白質之甘露糖含量之方法
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
US8956830B2 (en) 2013-03-14 2015-02-17 Momenta Pharmaceuticals, Inc. Methods of cell culture
WO2014151230A2 (en) 2013-03-15 2014-09-25 Bristol-Myers Squibb Company Method of treating granulomatosis with polyangiitis
WO2014170866A2 (en) * 2013-04-18 2014-10-23 Dr. Reddy's Laboratories Limited Process of obtaining glycoprotein composition with increased galactosylation content
WO2015051293A2 (en) 2013-10-04 2015-04-09 Abbvie, Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
TWI642782B (zh) * 2013-10-23 2018-12-01 健臻公司 重組醣蛋白及其用途
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
BR112016017630A2 (pt) * 2014-01-30 2017-08-08 Coherus Biosciences Inc Meios de perfusão
WO2015164595A1 (en) 2014-04-25 2015-10-29 Bristol-Myers Squibb Company Use of ctla4 compound for achieving drug-free remission in subjects with early ra
KR102434588B1 (ko) 2014-06-18 2022-08-22 메디뮨 엘엘씨 N-아세틸시스테인을 포함하는 세포 배양 방법 및 배지
JP6479974B2 (ja) 2014-10-15 2019-03-06 アレクシオン ファーマシューティカルズ， インコーポレイテッド 大規模エクリズマブ産生細胞培養を再現する方法
EP3072957B1 (en) 2015-03-23 2019-07-10 Lonza Ltd Methods for controlling protein glycosylation
EP3875477A1 (en) 2015-04-17 2021-09-08 Alpine Immune Sciences, Inc. Immunomodulatory proteins with tunable affinities
EP3322813A1 (en) * 2015-07-13 2018-05-23 Life Technologies Corporation System and method for improved transient protein expression in cho cells
MY197562A (en) 2015-09-21 2023-06-23 Aptevo Res & Development Llc Cd3 binding polypeptides
WO2017083224A1 (en) 2015-11-09 2017-05-18 Bristol-Myers Squibb Company Methods to manipulate quality attributes of polypeptides produced in cho cells
BR112018073909A2 (pt) * 2016-06-02 2019-02-26 Klotho Therapeutics, Inc. proteínas klotho recombinantes terapêuticas e composições e métodos envolvendo as mesmas
CA3041910A1 (en) 2016-11-22 2018-05-31 Klotho Therapeutics, Inc. Novel recombinant klotho proteins and compositions and methods involving the same
US11753458B2 (en) 2017-10-10 2023-09-12 Alpine Immune Sciences, Inc. CTLA-4 variant immunomodulatory proteins and uses thereof
CN111321188A (zh) * 2018-12-17 2020-06-23 嘉和生物药业有限公司 一种抗体糖型改造的配方、细胞培养方法以及在工业化生产中的应用
NZ781143A (en) 2019-12-06 2023-05-26 Regeneron Pharma Anti-vegf protein compositions and methods for producing the same
CN113025648B (zh) * 2019-12-09 2023-06-02 广东菲鹏制药股份有限公司 Expi293细胞瞬时表达目标蛋白的方法及其应用
CN111676184B (zh) * 2020-05-15 2021-01-29 上海多宁生物科技有限公司 一种由补料培养基共混的基础培养基及其制备方法和应用
EP4196597A2 (en) * 2020-08-14 2023-06-21 Bristol-Myers Squibb Company Manufacturing process for protein
WO2022162700A1 (en) * 2021-02-01 2022-08-04 Dr. Reddy's Laboratories Limited Cell culture methods
CN116830204A (zh) 2021-02-08 2023-09-29 株式会社岛津制作所 估计装置、学习装置、优化装置、估计方法、学习方法以及优化方法

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4357422A (en) 1980-08-14 1982-11-02 Massachusetts Institute Of Technology Method of enhancing interferon production
FR2543158B1 (fr) * 1983-03-24 1985-11-15 Inst Nat Sante Rech Med Milieu de culture de cellules animales sans serum, sans hormones et sans facteurs de croissance et procedes de culture primaire et d'obtention de lignees cellulaires utilisant ce milieu
US4994387A (en) 1983-11-10 1991-02-19 The Wistar Institute Process and medium for cloning and long-term serial cultivation of human endothelial cells
US5132223A (en) 1983-11-10 1992-07-21 Thomas Jefferson University Process and medium for cloning and long-term serial cultivation of adult human endothelial cells
US5112749A (en) * 1987-10-02 1992-05-12 Praxis Biologics, Inc. Vaccines for the malaria circumsporozoite protein
DE3801236A1 (de) * 1988-01-18 1989-07-27 Boehringer Mannheim Gmbh Pentosansulfat-medium
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6685941B1 (en) 1988-11-23 2004-02-03 The Regents Of The University Of Michigan Methods of treating autoimmune disease via CTLA-4Ig
CA2003455C (en) 1988-11-23 2000-02-22 Craig B. Thompson Immunotherapy involving cd28 stimulation
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US6641809B1 (en) 1990-03-26 2003-11-04 Bristol-Myers Squibb Company Method of regulating cellular processes mediated by B7 and CD28
US7070776B1 (en) 1990-03-26 2006-07-04 Bristol-Myers Squibb Company Methods for blocking binding of CD28 receptor to B7
GB9022545D0 (en) † 1990-10-17 1990-11-28 Wellcome Found Culture medium
US5318898A (en) 1991-04-02 1994-06-07 Genetics Institute, Inc. Production of recombinant bone-inducing proteins
TW318142B (sl) 1991-06-03 1997-10-21 Mitsubishi Chemicals Co Ltd
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
DE69226871T3 (de) 1991-06-27 2009-09-24 Bristol-Myers Squibb Co. CTL4A-Rezeptor, ihn enthaltenden Fusionsproteine und deren Verwendung
US6090914A (en) 1991-06-27 2000-07-18 Bristol-Myers Squibb Company CTLA4/CD28Ig hybrid fusion proteins and uses thereof
US5844095A (en) 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US5770197A (en) 1991-06-27 1998-06-23 Bristol-Myers Squibb Company Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules
ATE272708T1 (de) 1992-04-07 2004-08-15 Univ Michigan Immunregulation über die cd28-route
US5773253A (en) 1993-01-22 1998-06-30 Bristol-Myers Squibb Company MYPPPY variants of CTL A4 and uses thereof
US5348877A (en) 1993-03-12 1994-09-20 Boyce Thompson Institute For Plant Research, Inc. Method of adapting anchorage-dependent cell lines to suspension conditions
WO1994028912A1 (en) 1993-06-10 1994-12-22 The Regents Of The University Of Michigan Cd28 pathway immunosuppression
SE9303601D0 (sv) * 1993-11-01 1993-11-01 Kabi Pharmacia Ab Improved cell cultivation method and medium
EP0763057B1 (en) * 1994-04-28 2005-11-09 Boehringer Ingelheim Pharmaceuticals Inc. Method for proliferating and differentiating b cells, and uses thereof
US6719972B1 (en) 1994-06-03 2004-04-13 Repligen Corporation Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA4- specific antibodies
AU5014896A (en) 1995-03-24 1996-10-16 Takeda Chemical Industries Ltd. Antibody to human betacellulin and use thereof
US5721121A (en) 1995-06-06 1998-02-24 Genentech, Inc. Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
US5705364A (en) 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
WO1997005484A1 (en) * 1995-07-28 1997-02-13 Beth Israel Deaconess Medical Center, Inc. A method of and test kit for mutagenesis testing
JP4306813B2 (ja) * 1995-09-19 2009-08-05 アスビオファーマ株式会社 動物細胞の新規培養方法
US6750334B1 (en) 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
US5728580A (en) * 1996-02-20 1998-03-17 Cornell Research Foundation, Inc. Methods and culture media for inducing single cell suspension in insect cell lines
US6043092A (en) * 1996-03-18 2000-03-28 University Of Pittsburgh Cell culture media for mammalian cells
CA2246352C (en) 1996-03-20 2011-11-08 Bristol-Myers Squibb Company Methods for inhibiting an immune response by blocking the gp39/cd40 and ctla4/cd28/b7 pathways and compositions for use therewith
US5856159A (en) 1996-03-27 1999-01-05 Cytel Corporation Production of galactosyltransferase
US5851800A (en) 1996-05-14 1998-12-22 Pharmacia & Upjohn Ab Process for producing a protein
EP1482031B1 (en) 1996-08-30 2015-10-28 Life Technologies Corporation Serum-free mammalian cell culture medium, and uses thereof
ZA98533B (en) 1997-01-31 1999-07-22 Bristol Myers Squibb Co Soluble CTLA4 mutant molecules and uses thereof.
US20030219863A1 (en) 1997-01-31 2003-11-27 Bristol-Myers Squibb Company Soluble CTLA4 mutant molecules and uses thereof
ATE309350T1 (de) † 1997-12-03 2005-11-15 Roche Diagnostics Gmbh Verfahren zur herstellung von polypeptiden mit geeigneter glykosilierung
DE69929198T2 (de) 1998-05-29 2006-08-10 Genentech, Inc., South San Francisco Zellkulturverfahren für die produktion von glycoproteinen
DE19852729A1 (de) * 1998-11-16 2000-05-18 Werner Reutter Rekombinante Glycoproteine, Verfahren zu ihrer Herstellung, sie enthaltende Arzneimittel und ihre Verwendung
AU773845B2 (en) * 1998-11-18 2004-06-10 Neose Technologies, Inc. Low cost manufacture of oligosaccharides
TR200504220T2 (tr) 1998-12-17 2007-04-24 Biogen Idec Ma Inc. Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem.
PT1171615E (pt) 1999-04-26 2007-03-30 Genentech Inc Processo de cultura celular para glicoproteínas
WO2001059075A1 (en) 2000-02-08 2001-08-16 Genentech, Inc. Improved sialylation of glycoproteins
AU783973B2 (en) 2000-02-08 2006-01-12 Genentech Inc. Improved galactosylation of recombinant glycoproteins
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
PT1248802E (pt) * 2000-05-26 2004-11-30 Bristol Myers Squibb Co Moleculas mutantes de ctla4 soluveis e as suas utilizacoes
AU7541101A (en) 2000-06-09 2001-12-24 Bristol Myers Squibb Co Methods for regulating a cell-mediated immune response by blocking lymphocytic signals and by blocking lfa-1 mediated adhesion
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
SK287940B6 (sk) 2000-07-03 2012-05-03 Bristol-Myers Squibb Company Soluble CTLA4 fusion molecule, pharmaceutical composition comprising thereof and its use
US20020099183A1 (en) * 2000-08-23 2002-07-25 Pluschkell Stefanie Beate Process for the preparation of neutrophil inhibitory factor
WO2002058729A2 (en) 2001-01-26 2002-08-01 Emory University Methods of inducing organ transplant tolerance and correcting hemoglobinopathies
JP4837880B2 (ja) 2001-05-23 2011-12-14 ブリストル−マイヤーズ スクイブ カンパニー 可溶性ｃｔｌａ４突然変異体分子を使って同種異系島移植片を保護する方法
AU2003249055B2 (en) † 2002-07-15 2008-06-26 Immunex Corporation Methods and media for controlling sialylation of proteins produced by mammalian cells
US6924124B1 (en) * 2002-08-23 2005-08-02 Immunex Corporation Feeding strategies for cell culture
WO2004058944A2 (en) * 2002-12-23 2004-07-15 Bristol-Myers Squibb Company Product quality enhancement in mammalian cell culture processes for protein production
MXPA05006523A (es) 2002-12-23 2005-08-26 Squibb Bristol Myers Co Procesos de cultivo de celulas de mamiferos para la produccion de proteinas.
MXPA06001225A (es) 2003-08-04 2006-04-11 Bristol Myers Squibb Co Metodos de tratamiento de enfermedad cardiovascular usando una molecula soluble de ctla4.
WO2008060307A2 (en) * 2006-01-09 2008-05-22 Wyeth Methods of labeling transiently expressed proteins in large-scale eukaryotic cell cultures

Also Published As

Publication number Publication date
JP2006511224A (ja) 2006-04-06
TW200504221A (en) 2005-02-01
IL168873A (en) 2013-04-30
EP1576182A4 (en) 2007-05-02
EP1576182B2 (en) 2020-01-15
US20080070280A1 (en) 2008-03-20
CN1820080A (zh) 2006-08-16
US7332303B2 (en) 2008-02-19
PT1576182E (pt) 2011-01-21
DK1576182T4 (da) 2020-04-20
WO2004058944A3 (en) 2004-09-10
MXPA05006522A (es) 2006-02-17
US20050084933A1 (en) 2005-04-21
DE60335024D1 (de) 2010-12-30
WO2004058944A2 (en) 2004-07-15
KR101088223B1 (ko) 2011-11-30
TWI328614B (en) 2010-08-11
ES2354610T5 (es) 2020-09-14
EP1576182A2 (en) 2005-09-21
HK1075474A1 (en) 2005-12-16
EP1576182B1 (en) 2010-11-17
ES2354610T3 (es) 2011-03-16
JP4496086B2 (ja) 2010-07-07
KR20050103466A (ko) 2005-10-31
WO2004058944A8 (en) 2005-07-21
AU2003303394A1 (en) 2004-07-22
CN100402660C (zh) 2008-07-16
CY1111358T1 (el) 2015-08-05
AU2003303394B2 (en) 2009-02-19
SI1576182T1 (sl) 2011-01-31
ATE488600T1 (de) 2010-12-15
BR0316882A (pt) 2005-10-25
CA2508925C (en) 2012-08-28
CA2508925A1 (en) 2004-07-15
DK1576182T3 (da) 2011-02-21
CO5590971A2 (es) 2005-12-30
PL377603A1 (pl) 2006-02-06

Similar Documents

Publication Publication Date Title
HK1075474A1 (en) Product quality enhancement in mammalian cell culture processes for protein production
TW200512297A (en) Mammalian cell culture processes for protein production
Ljunggren et al. Catabolic control of hybridoma cells by glucose and glutamine limited fed batch cultures
HK1080115A1 (en) Cultures of e1-immortalized cells and processes for culturing the same to increase product yields therefrom e1-
WO2002101019A3 (en) Methods of culturing animal cells and polypeptide production in animal cells
MX2012003654A (es) Metodos de produccion de glucoproteinas en cultivos de celulas de mamiferos usando glucocorticoides.
PL376381A1 (en) Methods and media for controlling sialylation of proteins produced by mammalian cells
UA92157C2 (ru) Способ продуцирования гормона роста
PL1623019T5 (pl) Ograniczone zasilanie glukozą w hodowli komórek zwierzęcych
ATE79900T1 (de) Tierzellenkultur.
EP3495491A1 (en) Method for producing recombinant protein
AU2020101953A4 (en) A method of cultivating microalgae with high oil content
NZ515762A (en) Method of producing a heparin-binding protein by expressing it in a mammalian cell that can be cultured in anaerobic conditions
JP2018198580A (ja) 有機酸産出促進剤、有機酸の製造方法及び培養方法
BRPI0517942B8 (pt) processo para a produção do hormônio de crescimento humano recombinante (rhgh) e usos de um meio de cultura de células isento de soro
DE59911877D1 (de) Verfahren zur verbesserung des gentransfers von genetischem material in säugerzellen durch die verwendung von p21 (waf-1)
Franěk et al. Increasing monoclonal antibody productivity by semicontinuous substitution of production medium for growth medium
Blake et al. Cell culture
GB9828624D0 (en) Production of proteins
RU2008100689A (ru) Способ получения белкового гидролизата
ŠRÁMKOVÁ INCREASING MONOCLONAL ANTIBODY PRODUCTIVITY BY SEMICONTINUOUS SUBSTITUTION OF PRODUCTION MEDIUM FOR GROWTH MEDIUM
UA81564C2 (ru) Способ дифференциации стромальных столбовых клеток человека в культуральной среде in vitro
CN104830750A (zh) 一种驴皮成纤维细胞体外快速培养的方法